How Supportive Care Methods Can Improve Oncology Outcomes

Commentary
Podcast

Experts discussed supportive care and why it should be integrated into standard oncology care.

The latest episode of Oncology On the Go focused on survivorship and supportive care. Stemming from conversations with leading clinicians in the field, the compilation highlights gaps and educational insights into multiple areas.

Covering topics like nutrition, oncodermatology, body image, sexual health, and mortality, these conversations explored how to truly optimize multidisciplinary cancer care.

Declan Walsh, MD, chair of the Department of Supportive Oncology at Atrium Health Levine Cancer Institute:

1:01-2:44: What is the importance of developing and managing supportive care at major oncology centers, and how can it be adapted across the US?

2:45-4:19: Supportive care is one piece of the multidisciplinary team. How can clinicians work with supportive care specialists to ensure that patients are receiving all the help that they need?

Denise Reynolds, RD, of Atrium Health Levine Cancer Institute:

4:20-5:46: Some adverse effects (AEs) include severe nausea and vomiting. What nutritional strategies do you recommend to ensure adequate intake?

5:47-7:29: Taste and smell changes are common AEs. What advice do you give to patients to help cope and combat them?

Adam Friedman, MD, FAAD, professor and chair of dermatology, director of the Residency Program, and director of translational research at George Washington Medical Faculty Associates in Washington, DC:

7:30-9:24: Your study found that a significant proportion of respondents, including those who have been previously treated for cancer, would decline anti-cancer therapies due to dermatologic AEs like hair loss. What are some crucial communication strategies oncologists should employ to address this?

9:25-11:37: What should all oncology clinicians know about how to manage mild to moderate dermatologic AEs?

11:38-24:54: Daniel C. McFarland, DO, the director of the Psycho-Oncology Program at Wilmot Cancer Center; a medical oncologist who specializes in head, neck, and lung cancer; and the psycho-oncology editorial advisory board member for the journal ONCOLOGY®, spoke with different psycho-oncology colleagues regarding topics like body image, sexual health, and mortality.

These colleagues included Michelle Fingeret, PhD, founder of Fingeret Psychology Services; Christian J. Nelson, PhD, chief of Psychiatry Service, attending psychologist, and codirector of the Psycho-Oncology of Care and Aging Program at Memorial Sloan Kettering Cancer Center; and William S. Breitbart, MD, attending physician and the Jimmie C. Holland Chair in Psycho-Oncology at Memorial Sloan Kettering Cancer Center.

All psycho-oncology episodes are now available on our website.

Reference

Menta N, Vidal SI, Whiting C, Azim SA, Desai S, Friedman A. Perceptions and knowledge of dermatologic side effects of anti-cancer therapies: a pilot survey. J Drugs Dermatol. 2025;24(8):e57-e58.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to expect at the 43rd Annual Chemotherapy Foundation Symposium, such as new chemotherapeutics and targeted therapies.
In neuroendocrine tumor management, patients with insulinoma may be at risk of severe hypoglycemia following receipt of GLP-1 receptor agonists.
Trials at scale can be conducted in middle-income, low-middle-income, and even lower-income countries if you organize a trial ecosystem.
For example, you have a belt of certain diseases or genetic disorders that you come across, such as sickle cell disease or thalassemia, that are more prevalent in these areas.
Talent shortages in the manufacturing and administration of cellular therapies are problems that must be addressed at the level of each country.
Point-of-care manufacturing, scalable manufacturing, and bringing the cost down [can help].
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
A consolidated database may allow providers to access information on a patient’s prior treatments and genetic abnormalities all in 1 place.